Bristol-Myers Squibb (BMY) Tops Q3 EPS by 14c, Offers FY20 and FY21 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Bristol Myers Squibb Reports Third Quarter 2020 Financial Results
November 5, 2020 6:59 AM ESTReports Third Quarter Revenues of $10.5 Billion Posts GAAP EPS of $0.82 and Non-GAAP EPS of $1.63 Extends and Strengthens Leading Cardiovascular Franchise with Planned MyoKardia Acquisition Delivers Significant Pipeline and Regulatory Milestones Achieves Positive Results from POETYK-PSO-1 Evaluating Deucravacitinib (TYK2 inhibitor) for the Treatment of Moderate to Severe Plaque Psoriasis Raises 2020 GAAP and Non-GAAP EPS Guidance; Reaffirms 2021 Non-GAAP EPS Guidance
NEW YORK--(BUSINESS... More
